CGM Wear Durability Patent Snapshot 2026
CGM wear durability patenting is heavily concentrated, with a single incumbent holding the dominant position across all major technology branches. The field has reached a plateau after a multi-year build-up, with the United States as the primary filing jurisdiction.
A heavily concentrated field dominated by one incumbent
The corpus spans 26 patent families, with Medtronic MiniMed Inc ranked first and holding the largest share of the top patent records among the three ranked applicants. The top five filers account for all of the combined total of the ranked applicants visible in this query, confirming near-total concentration.
The tier gap between Medtronic MiniMed Inc and the next-ranked applicants — Welldoc Inc and Tingo Medical Ltd, each with 5 patent records — is substantial. This two-tier structure leaves limited room for challengers to compete on volume alone.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Medtronic MiniMed Inc | 42 | |
| 2 | Welldoc Inc | 5 | |
| 3 | Tingo Medical Ltd | 5 |
Medtronic MiniMed’s visible position, spanning diagnostic sensing, fluid-delivery device integration, and electrochemical testing branches, signals deep cross-functional coverage that would require both breadth and specificity to circumnavigate.
Patent records published in the most recent 18–24 months are subject to publication lag and likely under-represent actual recent filings; trend readings for 2024–2026 should be interpreted cautiously. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Filing activity has plateaued; sensing and surgery branches dominate the technology mix
The annual filing trend reveals how activity in this niche has evolved since 2019, while the technology composition chart shows which IPC branches capture the most filings.
Annual filing trend
Activity was absent before 2019, then built across 2019–2024 with moderate annual volumes. The field has plateaued near its peak; the apparent zeros for 2025–2026 reflect publication lag rather than a real halt in activity and should not be read as a decline.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61B (Diagnosis & surgery) is the visible branch, reflecting the electrochemical sensing and in-vivo monitoring core of CGM wear. A61M (Devices for body fluids) is the second branch, covering wearable delivery and patch integration. G01N (Material analysis & testing) captures impedance-spectroscopy methods, while G16H (Healthcare informatics) remains a minor share — relevant for digital companion and data-management claims.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Sensor systems, devices, and methods for continuou…
Electrochemical impedance spectroscopy (EIS) may be used in conjunction with continuous glucose monitoring (CGM) to enable identification of valid and reliable sensor data, as well implementation of Smart Calibration algorithms. (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Use of electrochemical impedance spectroscopy (EIS… | 56 |
| 2 | Use of electrochemical impedance spectroscopy (EIS… | 44 |
| 3 | Methods for continuous glucose monitoring | 40 |
| 4 | Sensor systems, devices, and methods for continuou… | 28 |
| 5 | Use of electrochemical impedance spectroscopy (EIS… | 17 |
| 6 | In-vivo electrochemical impedance spectroscopy (EI… | 12 |
| 7 | Continuous glucose sensor and mounting assembly | 8 |
| 8 | Sensor systems, devices, and methods for continuou… | 6 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
Assignee snapshot from the current evidence set
The applicants below are visible in this query result. Because the evidence set is relatively small, read this section as a directional snapshot rather than a full competitive ranking.
Medtronic MiniMed Inc
Medtronic MiniMed Inc is ranked first with 42 patent records, spanning A61B (diagnosis & surgery), A61M (devices for body fluids), and G01N (material analysis & testing). This cross-branch coverage reflects integrated sensor-and-delivery system development. Momentum is flagged as a new entrant in the recent window, with 8 recent records — consistent with continued but measured activity at a mature stage.
families: 42Welldoc Inc
Welldoc Inc holds 5 patent records, focused on A61B (diagnosis & surgery) and G16H (healthcare informatics) — the latter being the only branch where a challenger has visible presence. Momentum is also flagged as a new entrant with 5 recent records, suggesting the entire portfolio is recent. The informatics emphasis differentiates Welldoc from the hardware-centric leader.
families: 5Frequently asked questions
The corpus contains 26 patent families in scope. This is a narrow, specialist niche relative to the broader CGM market, indicating that wear durability is still a focused sub-field rather than a widely contested area.
Medtronic MiniMed Inc is the leading filer, with 42 patent records. The next-ranked applicants — Welldoc Inc and Tingo Medical Ltd — each hold 5 patent records, reflecting a large tier gap between the leader and all challengers.
The field is at the Maturity stage. Annual filings have plateaued near their peak. This suggests the core technical approaches are well-established, and incremental or adjacent innovation is more likely to find uncontested ground than direct challenges to the visible sensing methods.
A61B (Diagnosis & surgery) is the visible branch, followed by A61M (Devices for body fluids), G01N (Material analysis & testing), and G16H (Healthcare informatics). The first three branches together account for the large majority of patent records, with G16H representing the smallest and sparsest share.
The United States leads with 28 patent records, followed by Europe (EPO) with 8 and Canada with 5. Australia and WIPO (PCT) each account for 4 records, with Austria, New Zealand, and Singapore each having 1. The US-centric pattern indicates that international coverage outside key English-speaking markets is limited.
No co-applicant filings were identified in the CGM wear durability corpus. The field appears to have developed through proprietary, single-assignee programs. This absence of recorded partnerships may indicate an opening for collaborative portfolio-building, particularly in the under-served G16H informatics branch.
Ready to map your own CGM wear durability Snapshot?
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.